-
Merck’s Two-Drug HIV Regimen Meets Phase 3 Trial Goals
21 Nov 2025 16:16 GMT
… 3 trial evaluating its once-daily, oral two-drug regimen … doravirine/islatravir (DOR/ISL) in treatment … the standard three-drug regimen bictegravir/emtricitabine/tenofovir … FDA has already accepted the company’s New Drug Application …
-
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
20 Nov 2025 12:48 GMT
… 47;emtricitabine/tenofovir alafenamidei) in a Phase III trial.
In … clinical development and chief medical officer Dr Eliav Barr … treatments.
“DOR/ISL is the first two-drug … you deserve! The Clinical Trials Arena Excellence Awards celebrate …
-
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection
20 Nov 2025 13:06 GMT
… daily oral bictegravir/emtricitabine/tenofovir alafenamidei [BIC … Food and Drug Administration (FDA) accepted the New Drug Application (NDA … as the anchor medicine in the treatment regimens based … trial, the MK-8591A-051 and MK-8591A-052 phase 3 trials …
-
<![CDATA[Merck’s 2-Drug HIV Regimen Shows Noninferiority to Standard 3-Drug Therapy]]>
20 Nov 2025 02:22 GMT
… diagnosed with HIV and were treatment-naïve. The double-blind … the standard 3-drug regimen bictegravir/emtricitabine/tenofovir … from this phase 3 trial with DOR/ISL … global clinical development and chief medical officer, Merck Research Laboratories …
-
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
19 Nov 2025 19:29 GMT
… GILD) sells bictegravir/emtricitabine/tenofovir alafenamidei as … safety objective of the trial was also met, with … Food and Drug Administration (FDA) accepted the New Drug Application (NDA) … HIV Treatment Works As Well As Top Drug In Late Trials
…
-
Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3 trial
18 Nov 2025 08:15 GMT
… -1 trial. The open-label trial evaluated the treatment responses … drug-drug interactions, and therefore may face challenges such as high pill … could offer a new medication option with convenient dosing … bictegravir 50 mg/emtricitabine 200 mg/tenofovir …
-
Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection
22 Nov 2025 00:59 GMT
… -up after discontinuation of medications in both CHB patients … of drug resistance to NAs.4 The ALLIANCE trial revealed … based on the clinical trials in China108–111 and … dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of …
-
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
15 Nov 2025 01:57 GMT
… bictegravir 50 mg/emtricitabine 200 mg/tenofovir … treatment gained approval from the US Food and Drug Administration (FDA … about others discovering their medication or adherence challenges. … deserve! The Clinical Trials Arena Excellence Awards celebrate …
-
Bictegravir/Lenacapavir Daily Combo Pill Maintains HIV Suppression
15 Nov 2025 00:37 GMT
… treatment-experienced individuals who have used multiple medications have developed extensive drug … These ARTISTRY-1 trial results demonstrate that … pill (bictegravir/tenofovir alafenamide/emtricitabine). … lenacapavir as separate pills, while the …
-
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
14 Nov 2025 01:20 GMT
… by the FDA snapshot algorithm. In the trial, BIC… drug-drug interactions, and therefore may face challenges such as high pill … bictegravir 50 mg/emtricitabine 200 mg/tenofovir … long-acting injectable HIV treatment medication administered twice-yearly. …
About
© 1995-2025